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Introduction: Previous studies have estimated the costs of skeletal-
related events (SREs) for patients with bone metastases of solid
tumors by tallying costs for services specifically attributable to these
events. This approach may underestimate costs if SREs indirectly
increase use of other services.
Methods: This is a retrospective observational study using a large
health insurance claims database. Patients with bone metastases of
lung cancer who experienced 1 SRE were matched to similar
patients without SREs based on propensity scores. Kaplan-Meier
estimated total medical care costs were compared for propensity-
matched samples of patients with SREs and without SREs.
Results: We identified 534 patients with lung cancer and bone
metastases, including 295 (55%) with 1 SRE. After matching,
there were 162 patients each in the SRE and no-SRE groups with
mean follow-up of 5.3 and 3.9 months, respectively. In the SRE
group, costs of treatment of SREs were $9,480 (95% CI $7,625 to
$11,374) per patient. Total medical care costs were $27,982 (95% CI
$15,921 to $40,625) greater for SRE versus no-SRE patients (p 
0.001).
Conclusions: The costs of SREs in patients with lung cancer and
bone metastases are substantial and potentially greater than previ-
ously estimated.
Key Words: Lung cancer, Bone metastases, Complications, Costs,
Observational study.
(J Thorac Oncol. 2006;1: 571–576)
Bone metastases are estimated to occur in 30% to 40% ofpatients with lung cancer.1 Metastatic tumor cells that
colonize the bone matrix induce activity of osteoclasts or
osteoblasts, resulting in osteolysis and potential excessive
bone formation, respectively, at the sites of tumor cell depos-
its. The abnormal bone metabolism leads to significant skel-
etal morbidity, including the following skeletal-related events
(SREs): bone pain, pathologic fracture, spinal cord compres-
sion, and hypercalcemia of malignancy. Radiotherapy to bone
or opioid analgesic therapy to palliate severe bone pain and
surgery to correct fractures or spinal deformities may be
required. These SREs result in impaired mobility and reduced
quality of life2,3 and have a significant negative impact on
survival.4
Bisphosphonates are potent inhibitors of resorption and
have proven safe and effective in the prevention of SREs in
patients with bone metastases of a variety of solid tumors.5–7
A recently completed phase III, double-blind, randomized
trial reported that treatment with intravenous zoledronic acid
reduces the incidence of skeletal complications among pa-
tients with lung cancer.8 Although the clinical benefits of
intravenous bisphosphonates in preventing SREs are now
well established, concerns have been expressed about the
costs of these agents.9 A study of pamidronate in the preven-
tion of SREs among patients with metastatic breast cancer
reported that its cost-effectiveness was relatively unfavorable
compared with other generally accepted medical therapies.10
However, the results of this analysis were particularly sensi-
tive to the assumed costs of SREs ($3,200-$3,500), which
were estimated based on expert opinion and assumption. In
more recent studies, the costs of SREs have been found to be
two to three times greater than these estimates. In a study that
used retrospective chart review to estimate the costs of
treatment of SREs in Dutch patients with prostate cancer, the
costs of treatment of SRE were approximately €7,000
($7,300).11 In a study using a large health insurance claims
database, the costs of treatment of SREs among patients with
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bone metastases of lung cancer (n 295) in the United States
was estimated to be almost $12,000.12
Although these two studies suggest that the costs of
treatment of SREs may be greater than previously estimated,
all previous studies considered only the costs of services of
that were specifically for the treatment of SREs. This ap-
proach may underestimate the total economic burden of SREs
if indirect effects of such events—such as impaired functional
status as a consequence of fracture—increase the use of other
medical care services (e.g., office visits, need for long-term
care). To accurately assess the benefits of therapies to prevent
SREs, it is necessary to consider the both the direct and
indirect effects of SREs on total medical care costs. The
purpose of this study was to estimate the impact of SREs on




This was a retrospective observational study using data
from a large health insurance claims database. From a cohort
of patients with diagnoses of lung cancer and bone metasta-
ses, we identified patients who experienced one or more SRE
(SRE patients). These patients were then matched to similar
patients who did not experience a SRE (no-SRE patients)
based on propensity scores.13,14 Total medical care costs were
then compared for SRE and no-SRE patients.
Data Source
The Constella Health Strategies Private Benefit Plan
Database I is comprised of all health insurance claims (med-
ical and pharmacy bills submitted by providers) for persons
enrolled in various managed care plans of one of the largest
health benefits companies in the United States. Plans repre-
sented in the database provide coverage to approximately 3
million members annually. The database contains informa-
tion on member demographics, dates of eligibility for health
benefits, and use and billed charges for covered services,
including hospitalizations, outpatient procedures, physicians’
office visits, outpatient prescriptions, and home and long-
term care. Data available for each facility (e.g., hospital) and
professional service (e.g., physician) claim include dates of
service and International Classification of Diseases (ICD-9-
CM) diagnosis codes. Facility claims also include ICD-9-CM
procedure codes and discharge disposition. Professional ser-
vice claims also include Current Procedural Terminology
(CPT-4) procedure codes. Data available for each prescrip-
tion include the drug dispensed (in National Drug Code
[NDC] format), the dispensing date, and the quantity and
number of therapy-days dispensed. Most claims also include
information on billed charges and paid amounts. Information
on date of death is available from enrollment files, discharge
disposition on facility claims, and, for persons who died on or
before August 31, 2000, linked data from the United States
Social Security Administration. The dataset is updated and
archived on a periodic basis. Data for this study spanned the
period from July 1, 1994 to June 30, 2002, the most recent
8-year period for which complete claims and enrollment
information were available (the study period).
Study Subjects
We selected all persons in the database with two or
more encounters (an encounter being defined as one or more
medical claims on a given day) between July 1, 1995 and
June 30, 2002 with a diagnosis of primary lung cancer
(ICD-9-CM 162) and two or more encounters with a diagno-
sis of secondary malignant neoplasms of bone and bone
marrow (ICD-9-CM 198.5; bone metastases) anytime on or
after the date of the first claim with a diagnosis of lung
cancer. Persons with a diagnosis for other primary malig-
nancy (e.g., breast or prostate cancer) before the date of first
claim for lung cancer were excluded, as were those with
Medicare supplemental insurance (for whom complete claims
data may not be available), those with less than 6 months of
continuous enrollment before the date of first diagnosis of
bone metastases (for whom data with which to identify
comorbid conditions would be limited), and those younger
than 35 years of age at the first diagnosis of bone metastases.
SRE patients were then identified based on the presence
of either: (1) one or more encounters with a diagnosis code
for pathological fracture, spinal cord compression, or hyper-
calcemia; or (2) a procedure code for bone surgery or thera-
peutic radiology (although body site modifiers are unavail-
able for procedure codes for radiotherapy, most such
procedures in this population are likely directed to bone); or
(3) initiation of opioid analgesic therapy. Patients were con-
sidered to have experienced pathological fracture if they had
either: (1) two or more encounters with a diagnosis of
pathological fracture of bones commonly involved in meta-
static disease (i.e., the skull, ribs, sternum, vertebrae, or long
bones of the arms and legs); or (2) two or more encounters
with a diagnosis of non-pathological fracture of such bones in
the absence of concurrent severe trauma. Concurrent severe
trauma was identified based on one or more encounter, on the
date of the encounter for the non-pathological fracture, of any
of the following: (1) two or more fractures on the same day;
(2) multiple trauma or trauma to other systems; or (3) acci-
dent or injury other than fall on the same level.
Patients with bone metastases of lung cancer who
experienced SREs were matched to similar patients who did
not experience SREs using propensity-score matching.13,14
This technique is useful for matching subjects on multiple
characteristics simultaneously to control for differences be-
tween groups in these characteristics. A propensity score was
calculated for all patients by estimating a logistic regression
model with occurrence of a SRE as the dependent variable
and other patient characteristics (i.e., age, sex, additional sites
of metastases, etc.) as independent variables. The propensity
score for each patient was defined as the predicted probability
(range, 0-1) of experiencing a SRE conditional on the ob-
served values of other characteristics. To match patients, we
arrayed all possible pairs of SRE and no-SRE patients,
calculated for each pair the difference in the propensity score,
and discarded all pairs for which this difference was 0.01.
To avoid potential immortal time bias,15 we excluded all pairs
for which survival time of the no-SRE patient was less than
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the time from diagnosis of bone metastases to date of first
SRE of the corresponding SRE patient. Matched pairs were
ranked by difference in propensity score. The pair with the
smallest difference in propensity score was selected for the
analysis. This process was repeated until there were no pairs
remaining. Patients for whom a match could not be obtained
were excluded from the analysis.
For each patient in the SRE group, we defined the index
date as the date of the first SRE, and the time to SRE as the
difference between the date of the first diagnosis of bone
metastases and the index date. For each patient in the no-SRE
group, we defined the index date as the date of first diagnosis
for bone metastases plus the time to SRE for the matched
SRE patient. The follow-up period was defined for each
patient as the period beginning with the index date and ending
with the date of disenrollment from the health plan, end of the
study period, death, or 24 months post-index, whichever
occurred first.
Patient Characteristics
Information on age, gender, region (South or other),
and plan type (health maintenance organization or other) was
obtained from enrollment files. Diagnosis codes on facility
and professional service claims before the index date were
scanned to identify evidence of additional metastases to
brain, liver, or other sites, and comorbid conditions including
anemia, congestive heart failure, chronic obstructive pulmo-
nary disease, cardiovascular disease (ischemic heart disease,
stroke/transient ischemic attack, peripheral arterial disease),
diabetes, gastrointestinal and fluid disturbances, osteoarthri-
tis, and osteoporosis. Deyo’s version of the Charlson Comor-
bidity Index was calculated for each patient based on comor-
bidities present on or before the index date.16 Receipt of
hormonal therapy, chemotherapy, or radiotherapy during the
6 months before the index date was identified. The numbers
of outpatient and emergency room visits, inpatient days, and
hospitalizations during this period also were calculated, as
were total costs. Hospital costs were estimated by stepping
down billed charges using the national average Medicare
cost-to-charge ratio.17 Costs of all other services were ap-
proximated by billed charges. Because the dataset has miss-
ing or invalid charge data for a proportion of claims (because
of capitation arrangements with providers), charges for these
claims were imputed using data from claims for which charge
data were available. All costs were adjusted to 2002 price
levels using the United States Consumer Price Index for
Medical Care.18
Outcome Measures
Measures of interest included the cost of medical care
for the treatment of SREs, other medical care costs, and total
medical care costs. All costs were examined during a maxi-
mal follow-up of 24 months post-index. The cost of SRE
treatment included the costs of all claims with a diagnosis of
pathological fracture; spinal cord compression; or hypercal-
cemia, bone surgery, or radiotherapy procedures; new pre-
scription for opioid analgesics; or diagnostic radiology, phys-
ical therapy, or acupuncture procedure or prescription for a
non-steroidal anti-inflammatory drug (NSAID) within 7 days
of another SRE-related claim. Costs of care for specific types
of SRE and costs for specific categories of medical care
service (inpatient care, outpatient care, outpatient pharmacy,
etc.) also were examined. Because any given claim might
qualify for more than one type of SRE, claims were assigned
to specific types using a hierarchy based on contribution to
total costs among all patients in the sample. As we were
interested in estimating costs that might be avoided by pre-
ventive therapies, costs of bisphosphonate therapy were con-
servatively excluded from all calculations. Fewer than 10%
of lung cancer patients with bone metastases received such
therapy.
Statistical Analysis
Baseline demographic and clinical characteristics were
compared between SRE patients and matched no-SRE con-
trols using the signed rank test for continuous variables and
the McNemar test for categorical variables. Expected costs
for each group were calculated using the Kaplan-Meier sam-
ple average method.19 This approach combines survival
curves (probabilities) with cost histories to estimate expected
cumulative costs over time, and it is useful when there is
censoring (loss to follow-up) and costs are not incurred
uniformly over time. To implement this approach, follow-up
was partitioned into 24 monthly intervals, and the probabil-
ities of survival to the beginning of each interval were
calculated for each group using Kaplan-Meier methods. Av-
erage costs during each month among subjects alive and not
censored as of the beginning of the month were then calcu-
lated for each group (mean monthly costs). Survival proba-
bilities were multiplied by corresponding mean monthly costs
and summed across months to calculate expected cumulative
costs at the end of each month for each group. Non-paramet-
ric bootstrapping (repeated resampling with replacement) was
used to calculate 95% confidence intervals (CIs) for these
estimates and standard deviations and p values for differences
between groups. In calculating p values, differences in ex-
pected costs between groups were assumed to be normally
distributed. Because estimated survival curves differed be-
tween SRE and no-SRE patients, we conducted a secondary
analysis in which we adjusted for differences in survival
between groups by using the pooled survival curve for the
two groups combined to calculate expected total costs. All
analyses were conducted using SAS statistical software, ver-
sion 8.2 (SAS Institute, Cary, NC).
RESULTS
We identified 534 patients with bone metastases of lung
cancer, of whom 295 (55%) experienced one or more SREs.
Among patients with SREs, 68% underwent radiotherapy,
35% experienced fracture, 19% received an opioid or
NSAID, 14% underwent bone surgery, 7% experienced hy-
percalcemia, and 6% experienced spinal cord compression.
Of the patients with SREs, 64% experienced only one type of
SRE, 25% experienced two types of SREs, and 11% experi-
enced three or more types of SREs.
After matching, there were 162 pairs of SRE and
no-SRE patients. The two groups were well matched with
respect to all baseline demographic and clinical characteris-
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tics (Table 1). Mean (SD) follow-up was 5.3  5.6 months
for SRE patients and 3.9  4.8 months for no-SRE patients
(p  0.004). Kaplan-Meier estimated median survival was
3.8 versus 2.5 months for SRE patients versus no-SRE
patients (p  0.048) (Figure 1). The difference in follow-up
between groups was therefore almost certainly a consequence
of the difference in survival between groups.
Mean monthly total costs were nominally greater for
SRE versus no-SRE patients in all months except month 24
post-index (Figure 2). The difference in mean monthly cost
was greatest in the first month of follow-up ($7,570). Of the
difference in costs between SRE and no-SRE patients, 66%
was accrued during the first 6 months of follow-up.
Kaplan-Meier estimated cumulative total medical care
costs at 24 months (obtained by multiplying survival proba-
bilities at the beginning of each month by corresponding
mean monthly costs among those remaining alive and not
censored and summing across months) were $27,982 (95%
CI, $15,921 to $40,625) greater for SRE patients ($59,391,
95% CI $48,642 to $70,314) than in no-SRE patients
($31,409, 95% CI $25,745 to $37,884) (P.001) (Figure 3).
Of the difference (SRE vs no-SRE) in total costs, 39% was
for inpatient hospital care, 34% for physicians’ office visits,
23% for hospital outpatient care, and 4% for other services.
For patients with SREs, Kaplan-Meier estimated cost of
SRE treatment at 24 months was $9,480 (95% CI, $7,625 to
$11,374) (Figure 4). Of this cost, 55% was associated with
radiotherapy, 25% with bone surgery, 15% with treatment of
fractures, and 5% with other SREs. Inpatient hospital care
accounted for 54% of the cost of SRE treatment, physicians’
office visits accounted for 28%, hospital outpatient care
accounted for 14%, and other services accounted for 3%.
Other costs (at 24 months) were $18,502 (95% CI, $6,521 to
$30,838) greater for SRE patients ($49,911; 95% CI, $39,762
to $60,538) than no-SRE patients ($31,409; 95% CI, $25,745
to $37,884) (p  0.004).
When we adjusted for the difference in survival be-
tween SRE and no-SRE patients by using the pooled survival
curve for both groups, the difference in total costs between
SRE and no-SRE patients was $22,162 ($55,655 vs.




(n  162) p
Age (yr) 66.7 (9.6) 66.4 (9.7) 0.857
Male 105 (64.8) 104 (64.2) 0.907
Additional sites of metastases 46 (28.4) 49 (30.2) 0.696
Comorbid conditions
Diabetes 33 (20.4) 33 (20.4) 1.000
CVD 42 (25.9) 41 (25.3) 0.896
COPD 98 (60.5) 94 (58.0) 0.655
Anemia 24 (14.8) 30 (18.5) 0.387
GI/Fluid disturbance 50 (30.9) 48 (29.6) 0.811
Osteoarthritis 38 (23.5) 38 (23.5) 1.000
Osteoporosis 7 (4.3) 7 (4.3) 1.000
Charlson index 3.8 (3.2) 3.8 (3.2) 0.976
Outpatient visits in past 6 mo 16.4 (15.5) 18.7 (20.8) 0.569
Inpatient days in past 6 mo 2.4 (6.2) 2.6 (5.8) 0.422
Duration of follow-up (mo) 5.3 (5.6) 3.9 (4.8) 0.004
Values are mean (SD) or n (%) and were calculated at index date. CVD, cardio-
vascular disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; GI, gastrointestinal.
FIGURE 1. Kaplan-Meier estimated survival by month
FIGURE 2. Mean monthly total medical care costs by
month.
FIGURE 3. Kaplan-Meier estimated cumulative total medi-
cal care costs by month.
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$33,493). Differences in survival between groups accounted
for $5,820 (21%) of the unadjusted difference in costs be-
tween SRE and no-SRE patients.
DISCUSSION
In this retrospective observational study of lung cancer
patients with bone metastases, we estimated the expected
costs of treatment of SREs to be approximately $9,500. When
patients with SREs were compared with a propensity-
matched sample of patients without such events, we found
that total costs of medical care during 24 months, including
costs of care not specifically for the treatment of SREs, were
almost $28,000 greater for SRE patients. These findings
suggest that earlier estimates of the costs of SREs, which
considered only the cost specifically for the treatment of
SREs, may have underestimated the full economic impact of
these events. It has been shown that events such as fracture
are associated with functional limitation,20 which in turn is
associated with increased costs.21 This may in part explain
our findings.
Our estimate of the costs of SRE treatment is similar to
that reported by Groot et al.11 for patients with bone metas-
tases of prostate cancer (€7,000 or $7,300) but substantially
greater than that reported by Hillner et al.10 in their study of
the cost-effectiveness of pamidronate among patients with
bone metastases of breast cancer ($3,200-$3,500). Estimates
by Hillner et al. were obtained by multiplying Medicare
payments by estimates of resources use for various SREs that
were based largely on expert opinion and assumption. Our
estimate, however, is based on actual health insurance claims
for a geographically diverse group of patients with bone
metastases of lung cancer seen in typical clinical practice and
therefore may be more representative of the actual costs of
these events.
Limitations of this study should be noted. First, patients
were selected for inclusion in our study based on the presence
of two or more claims with diagnosis of bone metastases.
Because not all patients who experience bone metastases
have claims with such a diagnosis, our sample may be
weighted toward those with the most severe disease.
Second, our sample was drawn from patients enrolled
in managed care plans located principally in the Midwestern
and Southern United States. Our results may not be general-
izable to patients in other countries, regions, or types of
health plans.
Third, as a consequence of the matching procedure we
used, approximately 45% of the 295 patients who experi-
enced SREs were dropped from our sample. In a previous
study of all 295 patients who experienced one or more SREs,
the expected costs of SRE-specific care was approximately
$12,000 per patient.12 Thus, our estimate of the cost of
treatment of SREs may be conservative.
Fourth, ICD-9-CM and CPT codes for radiotherapy do
not permit identification of the body site to which such
therapy was directed. We therefore assumed that all claims
for therapeutic radiotherapy were to bone. Although we
believe that most radiotherapy procedures in patients with
bone metastases of lung cancer are to bone, it is possible that
these procedures were directed at other metastatic sites. Our
estimate of SRE-related costs therefore may have been up-
wardly biased by the inclusion of the costs of radiotherapy to
non-bone sites. Patients who received radiotherapy only for
the treatment of non-osseous metastases could have been
misclassified as SRE patients. This might have biased our
comparison of SRE and no-SRE patients. We believe that any
such misclassification and bias were minimal, however, as the
proportion of patients with diagnoses of metastases to sites
other than bone was similar in the SRE and no-SRE groups
(28.4% vs. 30.2%; p  0.696). If radiotherapy to other sites
was common, one would have expected the SRE patients to
have a higher incidence of metastases to other sites.
Finally, because our study relied on health insurance
claims data and lacked information on a variety of clinical
characteristics that might be associated with risk of SRE on
the one hand and survival and costs on the other, it is possible
that the difference that we observed between SRE and no-
SRE patients in the costs of care not specifically for treatment
of SREs was the result of confounding from factors not
accounted for in our analysis. Our estimates of the additional
costs of such care should be interpreted cautiously.
CONCLUSION
The total costs of SREs in patients with lung cancer and
bone metastases are substantial and potentially greater than
previously estimated.
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